Rezafungin

Rezafungin, sold under the brand name Rezzayo (by Melinta Therapeutics), is a medication used for the treatment of invasive candidiasis. It is an echinocandin antifungal that acts as a fungal β-glucan synthase inhibitor. Rezafungin was approved for medical use in the United States in March 2023, and in the European Union in December 2023.
Wikipedia contributors, "Rezafungin", Wikipedia, revision 1384293798, retrieved 20 November 2026, source, CC BY-SA 4.0.